Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XRÂŽ (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XRÂŽ (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder. Source
No articles found.
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental...
Pluristem Therapeutics Inc. is a clinical-stage...
Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...
Seres Therapeutics, Inc. is a microbiome therap...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a bi...
Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and mark...
Akorn, Inc. is a niche pharmaceutical company t...
Hera Health Solutions is a pharmaceutical device company based in Memphis, Tenness...
Hera Health Solutions is a pharmaceutical devic...
We at Auris Medical are dedicated to developing novel pharmaceutical products for ...
We at Auris Medical are dedicated to developing...
Join the National Investor Network and get the latest information with your interests in mind.